Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy

Conclusions In patients failing an NRTI plus NNRTI-based regimen, to know the feasibility of a switch to rilpivirine/emtricitabine/tenofovir disoproxil fumarate, reliable resistance information should be available at the time of use of concurrent NNRTI therapy.

http://jac.oxfordjournals.org/cgi/content/short/69/4/1086?rss=1

Source: Journal of Antimicrobial Chemotherapy - March 17, 2014 Category: Microbiology Authors: Lambert-Niclot, S., Charpentier, C., Storto, A., Fofana, D., Soulie, C., Fourati, S., Wirden, M., Morand-Joubert, L., Masquelier, B., Flandre, P., Calvez, V., Descamps, D., Marcelin, A. G. Tags: Original research Source Type: research